164 results about "Targeted nanoparticles" patented technology

The present invention generally relates to yeast cell wall microparticles loaded with nanoparticles for receptor-targeted nanoparticle delivery. In particular, the present invention relates to trapping nanoparticles either on the surface or inside a yeast glucan particles, for example, yeast glucal particles. The present invention further relates to methods of making the yeast cell wall particles loaded with nanoparticles. The present invention also relates to methods of using the yeast cell wall particles loaded with nanoparticles for receptor-targeted delivery of the nanoparticles, e.g., drug containing nanoparticles.

The invention provides modified gold nanoparticles that enable a non-invasive, real time, targeted cancer imaging-therapeutic in one step. After reaching the cancer targets, the designed targeted gold nanoparticles significantly enhance conventional treatment modalities at the cellular level. In this aspect the gold nanoparticles of the invention are modified to be bound to a Positron Emission Tomography (PET) tracer.

Emulsions comprising nanoparticles formed from high boiling perfluorochemical substances, said particles coated with a lipid / surfactant coating are made target-specific by directly coupling said nanoparticles to a targeting ligand. The nanoparticle may further include biologically active agents, radionuclides, and / or other imaging agents, and are used to image and / or lyse blood clots in human subjects.

The preparation method includes the following steps: modifying hepatic target compound onto degradable polymer (chitosan, polylysine, glucosan, agar, polyglutamic acid-benzyl ester, polyalanine) with biological compatibility, and adopting ion exchange or ultrasonic emulsification process to obtain the invented nano hepatic target bio-degradable medicine carrier material. The hepatic target nano particle solution has good target performance for liver, the medicine enriched rate in the liver can be up to 75%, and its slowly-released administration can be up to above 15 days.

The present invention relates to a targeted magnetic nanoparticle drug and the preparation method thereof. The targeted magnetic nanoparticle drug comprises an effector molecule and a guidance molecule in a weight ratio of 1:0.0001-0.20. The aforesaid effector molecule is a magnetic particle, with a particle size of not more than 1000 nm and a specific adsorption rate (SAR) of 10-7000 W / gFe. The aforesaid guidance molecule comprises an antibody, a ligand or a magnetic particle. The particle size of the aforesaid targeted drug is 2-1000 nm. The targeted magnetic nanoparticle drug is prepared by coupling a magnetic particle and a guidance molecule in a weight ratio of 1:0.0001-0.20 in water, organic or inorganic substance or the mixed solution thereof. The resultant targeted magnetic nanoparticle drug can realize targeted magnetic hyperthermia treatment and targeted magnetic thermoablation treatment and prevention on the tumors, and effectively kill the cancer cells, and cure the malignant tumors.

The current invention is a novel superparamagnetic site-targeting nanoparticle comprising superparamagnetic nanoparticles encapsulated with a smart polymer. The superparamagnetic site-targeting nanoparticle comprises a functionalized superparamagnetic core that is conjugated with a therapeutic agent and then encapsulated with a smart polymer. The smart polymer can be any polymer that exhibits a reversible conformational or physio-chemical change in response to an external stimulus or stimuli.

The present invention includes delivery of isolated and purified nucleic acids that encode GTPCH proteins in nanoparticles for the treatment of endothelial cells damaged by diabetes, smoking, dyslipidemia, hypertension, and cardiovascular disease. The nanoparticles contain a nucleic acid sequence, polymer and a targeting ligand. The targeting ligand facilitates the selective delivery of the nucleic acid sequence to damaged endothelial cells. Examples involving a nucleic acid sequence encoding GTP-cyclohydrolase I (GTPCH), PEG / PEI polymers, and a monoclonal antibody or other molecule that binds to the lectin-like oxidized low density lipoprotein (LDL) receptor-1 (Lox-1) or associated molecules are presented.

This invention provides constructs comprising a targeting member immobilized on a detectable particulate, in which binding of the targeting member to a target structure on a surface of a cancer cell triggers internalization of the construct. Such constructs can be used to identify or monitor cancer cells in cell cultures or in a tissue. Such construct can also be used to kill or prevent growth of cancer cells in vivo. Also included in the invention are methods for killing or preventing growth of cancer cells in vivo.

A generic route for synthesis of asymmetric nanostructures. This approach utilizes submicron magnetic particles (Fe3O4—SiO2) as recyclable solid substrates for the assembly of asymmetric nanostructures and purification of the final product. Importantly, an additional SiO2 layer is employed as a mediation layer to allow for selective modification of target nanoparticles. The partially patched nanoparticles are used as building blocks for different kinds of complex asymmetric nanostructures that cannot be fabricated by conventional approaches. The potential applications such as ultra-sensitive substrates for surface enhanced Raman scattering (SERS) have been included.

Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.

Methods of non-invasive imaging of complement-mediated inflammation are provided. Compositions including CR-targeted ultrasmall superparamagnetic nanoparticles or aggregates thereof for use with those methods are also provided.

Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.

The present invention can provide a method of determining the presence, location, quantity, or a combination thereof, of a biological substance, comprising: (a) exposing a sample to a plurality of targeted nanoparticles, where each targeted nanoparticle comprises a paramagnetic nanoparticle conjugated with one or more targeting agents that preferentially bind with the biological substance, under conditions that facilitate binding of the targeting agent to at least one of the one or more biological substances; (b) subjecting the sample to a magnetic field of sufficient strength to induce magnetization of the nanoparticles; (c) measuring a magnetic field of the sample after decreasing the magnetic field applied in step b below a threshold; (d) determining the presence, location, quantity, or a combination thereof, of the one or more biologic substances from the magnetic field measured in step (c).

Emulsions comprising nanoparticles formed from high boiling perfluorochemical substances, said particles coated with a lipid / surfactant coating are made target-specific by directly coupling said nanoparticles to a targeting ligand. The nanoparticles may further include biologically active agents, radionuclides, and / or other imaging agents.

The invention provides methods and compositions for the delivery of bioactive factors to the systemic skeleton. The methods of the invention allow targeted delivery of bioactive factors to bone using nanocapsules comprised of amphipathic materials. Timed release of bioactive factors may also be used to increase the efficacy of treatment. The methods of the invention have wide applicability for the treatment or prevention of bone-associated maladies.

Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.

A dual-particle tumor targeting system comprising a first ligand-mediated targeting nanoparticle conjugated with galactosamine and a second EPR-mediated targeting nanoparticle, wherein said first and second nanoparticles are mixed in a solution configured for delivering to a target liver tumor.

Provided are nanoparticle conjugates comprising a drug encapsulated in a gelatin nanoparticle the surface of which is functionalized with an antibody to which a siRNA is linked. Methods with the nanoconjugates for treating diseases are provided as well.

The invention belongs to the technical field of biomedical polymer material and nanobiomaterial, particularly relates to a magnetic nano-carrier with targeted hydrophobic drug delivery to tumor and a preparation method thereof. The magnetic nano-carrier is formed by encapsulating superparamagnetic nano-particles with amphiphilic segmented copolymer methoxy polye thylene glycol-poly(lactide- glycolide) (MePEG-PLGA) micelles. First, a large amount of MePEG-PLGA with good dispersion is synthesized by the improved solution polymerization process, and then the MePEG-PLGA is used as raw materials to encapsulate Fe3O4 nano-particles by the solvent evaporation process to obtain a magnetic nano drug carrier. The carrier is expected to solve the solubility problem of insoluble drugs, achieves slow release of drugs, and achieves the passive-targeting of the drugs by the EPR effect of tumor; Fe3O4 nano-particles are used in the active-targeting of the drugs to reduce the dosage and the side effect and improve the treatment efficiency; besides, the carrier can be used in the magnetic resonance imaging (MRI) of tumor.

The invention discloses galactosamine and polydopamine modified liver cancer targeting nanoparticles as well as a preparation method and application thereof. The preparation method of the galactosamine and polydopamine modified liver cancer targeting nanoparticles comprises the following steps: taking polymer and a hydrophobic medicine, dissolving the polymer and the hydrophobic medicine into an organic solvent, stirring, dropwise adding the obtained solution into TPGS aqueous solution, stirring, carrying out reduced pressure volatilization, centrifuging, and abandoning supernate, so that polymer initial nanoparticles carrying the hydrophobic medicine are obtained; resuspending the initial nanoparticles in Tris buffer solution, adding dopamine hydrochloride for reacting, and centrifuging, so that hydrophobic-medicine-carrying nanoparticles wrapped by polydopamine are obtained; dispersing the hydrophobic-medicine-carrying nanoparticles wrapped by polydopamine into weakly alkaline aqueous solution, adding a liver cancer targeting ligand galactosamine, reacting, centrifuging, and carrying out freeze drying, so that the galactosamine and polydopamine modified liver cancer targeting nanoparticles are obtained. The preparation method of the galactosamine and polydopamine modified liver cancer targeting nanoparticles is simple and pollution-free; and the galactosamine and polydopamine modified liver cancer targeting nanoparticles have good liver targeting property, biological compatibility and biological degradability, can be used for targeting liver cancer and has treatment effect.

The invention provides a targeting nano carrier bearing nucleoside anti-tumor drugs and preparation method and application thereof. The targeting nano carrier comprises DNA tetrahedron, Affibody molecule and nucleoside anti-tumor drugs. The preparation method comprises the following steps: a, the nucleoside anti-tumor drugs are modified with phosphoramidite; B, synthesizing four DNA single strandsby DNA solid phase synthesis technology, integrating the nucleoside anti-tumor drugs into the 5 'ends of the four DNA single strands, and modifying NH2 at the 3' ends of one of the DNA single strands; C, linking the affibody molecule to the 3 'end of the NH2-modified DNA single strand through a linker; (d) mix and assembling that four DNA single strand in a molar ratio of 1: 1: 1: 1 to obtain DNAtetrahedron; and (d) assembling the four DNA single strands in a molar ratio of 1: 1: 1 to obtain DNA tetrahedron; Affibody targeting nanoparticles. The targeting nano carrier of the invention can precisely control the combined quantity of drugs, has faster tumor targeting ability and higher cell, tissue penetration ability, good pharmaceutical effect, and is suitable for popularization and application.

The invention discloses a nuclear magnetic resonance sensor for detecting melamine based on magnetic nanoparticles. The nuclear magnetic resonance sensor is a Fe / Fe3O4 magnetic nanoparticle containing an acceptor unit which is capable of specific recognition of melamine and having water-solubility, superparamagnetism, uniform particle size distribution and a particle size of about 10 to 20 nm. A preparation method for the sensor comprises the following steps: preparation of a Fe / Fe3O4 magnetic nanoparticle through high temperature pyrolysis; preparation of Dopa-PEG and Dopa-acceptor unit by using N-hydroxy succinimide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride; and preparation of a target nanoparticle for preparation of the nuclear magnetic resonance sensor used for detecting melamine in virtue of coordination of oxygen and connection of the nanoparticle. The preparation method provided by the invention has the advantages of easiness, safety, economy and easy availability of raw materials and good process controllability. According to the invention, a novel prospect--a nanometer magnetic resonance sensor is provided for application of a nanometer magnetic resonance contrast agent material, and the research area of nano-materials is broadened.

Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule.Further disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to anti-HER2 therapy; and administering to the patient a therapeutically effective amount of a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence. Finally disclosed herein are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence

The present invention relates to a technology for oral delivery of Poorly Bio-Available Therapeutic Agents and the formulations derived using this technology. Poorly Bio-Available Therapeutic Agents may belong to BCS class III / IV drugs or nutraceutical or any other agent which is required to be orally delivered having challenge of bio-availability in body. Therefore, invention further relates to a targeted delivery technology for enhanced bio-availability and controlled release without being degraded. The present invention further relates to the processes for the preparation of said compositions and formulations made thereof. The formulations of the present invention are useful to treat related conditions.

The present invention provides methods and apparatuses for detecting, measuring, or locating cells or substances present in even very low concentrations in vivo in subjects, using targeted magnetic nanoparticles and special magnetic systems. The magnetic systems can comprise magnetizing subsystems and sensors subsystems, including as examples SQUID sensors and atomic magnetometers. The magnetic systems can detect, measure, or location particles bound by antibodies to cells or substances of predetermined types. Example magnetic systems are capable of detecting sub-nanogram amounts of these nanoparticles.

The invention discloses a herceptin modified paclitaxel-carried targeting nanoparticle transfer system and a preparation method thereof. Nanoparticles (PLNs) with PLGA / Lipid core-shell structures are prepared by an improved classical emulsion solvent evaporation method, paclitaxel-carried polymer lipid nanoparticles are prepared by a binary organic solvent method, and herceptin modified paclitaxel-carried targeting nanoparticles (T=PCNs) are built by a chemical modification method. The prepared T=PCNs release drugs in vitro, sudden release rate within 24h is 41.2%, cumulative release rate within 120h is 73.4%, and cancer therapy is facilitated by drug release level. Cell experiment results indicate that the T=PCNs are fine in targeting property for highly expressed HER2 cancer cells and have an obvious killing function for the cancer cells. Safety and the targeting property of paclitaxel are greatly improved.

The invention discloses photothermal conversion nanoparticles for targeted thermal elimination of Tregs. Hydrophilic functional groups grafted with long cycles and functional groups of targeted Tregs are arranged on the surfaces of the nanoparticles, and the particle sizes of the nanoparticles are within 2 to 100 nanometers; the nanoparticles comprise tungsten oxide nanoparticles or gold nanoparticles in a non-stoichiometric ratio, wherein the molecular formulae of the tungsten oxide nanoparticles in the non-stoichiometric ratio are WOx; the particle sizes of the tungsten oxide nanoparticles are within 2 to 100 nanometers; when the targeted nanoparticles are the gold nanoparticles, the particle sizes of the targeted nanoparticles are within 1 to 200 nanometers, and the shapes of the targeted nanoparticles are one or more of spheres, triangles or rod-like structures; according to the invention, the Tregs are removed from tumor tissues, so that the inhibition of the Tregs for the activity of cytotoxic T cells can be blocked, furthermore, heat produced by a photothermal therapy stimulates the activation of the cytotoxic T cells in peripheral blood to weaken the immune tolerance of tumors and further stimulate the anti-tumor immune response, thereby achieving a specific killing effect on tumor cells.

Compositions that contain bioactive agent-loaded nanoparticles with heart targeting capabilities and methods of using the same for the treatment of disease are disclosed.